Tag: Progression

Posted on

Is It Justified to Sacrifice the Pituitary Stalk During Craniopharyngioma Surgery? A Systematic Review and Meta-Analysis

Neurosurgery 96:725–733, 2025

This systematic review and meta-analysis examined the impact of pituitary stalk sacrifice during craniopharyngioma surgery. It found that sacrificing the stalk significantly increases the risk of postoperative endocrine dysfunction without reducing tumor recurrence or progression, highlighting the importance of preserving the stalk when possible.

• Pituitary stalk sacrifice increases risk of endocrine dysfunction without reducing recurrence risk.

• Preservation of the pituitary stalk is recommended whenever possible.

• Fourteen studies with 2074 patients were included in the meta-analysis.

• Stalk sacrifice associated with higher endocrine dysfunction risk (OR = 6.69, P < .0001).

• No significant decrease in recurrence risk with stalk sacrifice (OR = 0.80, P = .13).

• Retrospective studies were included, no randomized trials.

• Endoscopic endonasal and transcranial approaches were evaluated.

• Molecular biology factors like β-catenin mutations affect recurrence risk.

• Confounding factors like age and preoperative endocrinopathy impact outcomes.

• Future prospective studies recommended to assess confounding factors.

• Stalk preservation linked to better outcomes in normal preoperative endocrine function.

• Radiation therapy recommended post-GTR for β-catenin positive cases to prevent progression.

• Stalk preservation does not increase recurrence/progression risk according to multiple studies.

Posted on

Natural history of meningiomas: a serial volumetric analysis of 240 tumors

J Neurosurg 137:1639–1649, 2022

The management of asymptomatic intracranial meningiomas is controversial. Through the assessment of growth predictors, the authors aimed to create the basis for practicable clinical pathways for the management of these tumors.

METHODS The authors volumetrically analyzed meningiomas radiologically diagnosed at their institution between 2003 and 2015. The primary endpoint was growth of tumor volume. The authors used significant variables from the multivariable regression model to construct a decision tree based on the exhaustive Chi-Square Automatic Interaction Detection (CHAID) algorithm.

RESULTS Of 240 meningiomas, 159 (66.3%) demonstrated growth during a mean observation period of 46.9 months. On multivariable logistic regression analysis, older age (OR 0.979 [95% CI 0.958–1.000], p = 0.048) and presence of calcification (OR 0.442 [95% CI 0.224–0.872], p = 0.019) had a negative predictive value for tumor growth, while T2-signal iso-/hyperintensity (OR 4.415 [95% CI 2.056–9.479], p < 0.001) had a positive predictive value. A decision tree model yielded three growth risk groups based on T2 signal intensity and presence of calcifications. The median tumor volume doubling time (Td) was 185.7 months in the low-risk, 100.1 months in the intermediate-risk, and 51.7 months in the highrisk group (p < 0.001). Whereas 0% of meningiomas in the low- and intermediate-risk groups had a Td of ≤ 12 months, the percentage was 8.9% in the high-risk group (p = 0.021).

CONCLUSIONS Most meningiomas demonstrated growth during follow-up. The absence of calcifications and iso-/ hyperintensity on T2-weighted imaging offer a practical way of stratifying meningiomas as low, intermediate, or high risk. Small tumors in the low- or intermediate-risk categories can be monitored with longer follow-up intervals.

Posted on

Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery

Neurosurgery 89:291–299, 2021

Currently, different postoperative predictors of chordoma recurrence have been identified. Tumor growth rate (TGR) is an image-based calculation that provides quantitative information of tumor’s volume changing over time and has been shown to predict progression-free survival (PFS) in other tumor types.

OBJECTIVE: To explore the usefulness of TGR as a new preoperative radiological marker for chordoma recurrence.

METHODS: A retrospective single-institution study was carried out including patients reflecting these criteria: confirmed diagnosis of chordoma on pathological analysis, no history of previous radiation, and at least 2 preoperative thin-slice magnetic resonance images available to measure TGR. TGR was calculated for all patients, showing the percentage change in tumor size over 1 mo.

RESULTS: A total of 32 patients were retained for analysis. Patients with a TGR ≥ 10.12%/m had a statistically significantly lower mean PFS (P<.0001). TGR≥10.12%/m (odds ratio=26, P=.001) was observed more frequently in recurrent chordoma. In a subgroup analysis, we found that the association of Ki-67 labeling index≥6% and TGR≥10.12%/m was correlated with recurrence (P = .0008).

CONCLUSION: TGR may be considered as a preoperative radiological indicator of tumor proliferation and seems to preoperatively identify more aggressive tumors with a higher tendency to recur. Our findings suggest that the therapeutic strategy and clinical radiological follow-up of patients with chordoma can be adapted also according to this new parameter.

Proudly powered by WordPress